Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT04555603 Withdrawn - Clinical trials for Renal Cell Carcinoma

Axitinib Therapy Management Study

Start date: September 15, 2020
Phase:
Study type: Observational

The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI

NCT ID: NCT04545827 Not yet recruiting - Colorectal Cancer Clinical Trials

Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours

Start date: June 2021
Phase: Phase 1
Study type: Interventional

A study to assess the safety of IMM-01 in participants with advanced solid tumors

NCT ID: NCT04544748 Active, not recruiting - Melanoma Clinical Trials

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

Start date: July 22, 2020
Phase: Phase 1
Study type: Interventional

It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.

NCT ID: NCT04540705 Completed - Clinical trials for Renal Cell Carcinoma

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

PIVOT IO 011
Start date: September 11, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.

NCT ID: NCT04535921 Completed - Prostate Cancer Clinical Trials

Fear of Cancer Recurrence in Genitourinary Cancer

Start date: November 5, 2019
Phase:
Study type: Observational

To perform an analysis of independent predictors of fear of cancer recurrence in patients with malignant genitourinary diseases and their impact on quality of life and survival

NCT ID: NCT04535687 Completed - Clinical trials for Renal Cell Carcinoma

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

This trial aims to prospectively assess the safety and efficiency of Fluzoparib in metastatic non-clear cell renal cell carcinoma

NCT ID: NCT04534998 Recruiting - Clinical trials for Renal Cell Carcinoma

Robotic-assisted vs. Open Partial Nephrectomy

ROBOCOP
Start date: June 15, 2020
Phase: Phase 2
Study type: Interventional

ROBOCOP is an open-label, randomized controlled feasibility trial comparing robotic-assisted and open partial nephrectomy in preparation for a confirmative phase III randomized controlled trial.

NCT ID: NCT04523272 Recruiting - Clinical trials for Advanced Renal Cancer

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Start date: August 25, 2020
Phase: Phase 3
Study type: Interventional

This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.

NCT ID: NCT04522323 Recruiting - Clinical trials for Advanced Renal Cell Carcinoma

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Start date: August 5, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.

NCT ID: NCT04518046 Completed - Clinical trials for Clear-Cell Renal Cell Carcinoma

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Start date: August 11, 2020
Phase: Phase 1
Study type: Interventional

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types.